BMS-986340 + Nivolumab/Docetaxel for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new drug, BMS-986340, alone and with other cancer treatments (nivolumab and docetaxel) in patients with advanced solid tumors. The goal is to find out if it is safe and effective in treating these cancers.
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, if you are on corticosteroids or other immunosuppressive medications, you may need to stop them 14 to 30 days before starting the study treatment.
Is the combination of BMS-986340 and Nivolumab/Docetaxel safe for humans?
What makes the drug BMS-986340 + Nivolumab/Docetaxel unique for cancer treatment?
This drug combination is unique because it includes BMS-986340, an anti-CCR8 antibody, which is a novel approach to targeting cancer cells, combined with Nivolumab, a PD-1 inhibitor that has shown improved survival rates over traditional chemotherapy like Docetaxel in non-small-cell lung cancer (NSCLC). This combination leverages the immune system to fight cancer more effectively than standard treatments.35678
What data supports the effectiveness of the drug BMS-986340 + Nivolumab/Docetaxel for cancer?
Who Is on the Research Team?
Bristol-Myers Squibb
Principal Investigator
Bristol-Myers Squibb
Are You a Good Fit for This Trial?
This trial is for adults with advanced solid tumors who've tried, can't tolerate, or have no other treatment options. They must have measurable disease and provide tumor biopsies for analysis. Not eligible if they had recent major surgery, are pregnant/breastfeeding, have certain lung diseases or autoimmune conditions, untreated brain metastases, or need steroids/immunosuppressants.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive BMS-986340 as monotherapy or in combination with nivolumab or docetaxel to assess safety, tolerability, and recommended dose(s)
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- BMS-936558-01
- BMS-986340
- Docetaxel
Find a Clinic Near You
Who Is Running the Clinical Trial?
Bristol-Myers Squibb
Lead Sponsor
Christopher Boerner
Bristol-Myers Squibb
Chief Executive Officer since 2023
PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis
Deepak L. Bhatt
Bristol-Myers Squibb
Chief Medical Officer since 2024
MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania